Molecular Partners Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
167
- Stock Symbol
-
MOLN
- Share Price
-
$4.81
- (As of Wednesday Closing)
Molecular Partners General Information
Description
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Contact Information
Website
www.molecularpartners.comCorporate Office
- Wagistrasse 14
- Schlieren
- 8952 Zurich
- Switzerland
Corporate Office
- Wagistrasse 14
- Schlieren
- 8952 Zurich
- Switzerland
Molecular Partners Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.81 | $4.74 | $3.38 - $10.74 | $157M | 33.2M | 19.2K | -$1.97 |
Molecular Partners Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 51,418 | (87,539) | (28,171) | 471,025 |
| Revenue | 8,860 | 7,829 | 198,523 | 10,205 |
| EBITDA | (67,080) | (70,984) | 125,367 | (66,469) |
| Net Income | (64,943) | (68,954) | 123,428 | (69,768) |
| Total Assets | 189,800 | 236,150 | 282,868 | 188,894 |
| Total Debt | 3,392 | 4,348 | 5,231 | 6,606 |
Molecular Partners Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Molecular Partners Comparisons
Industry
Financing
Details
Molecular Partners Competitors (56)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bluebird Bio | Formerly VC-backed | Somerville, MA | ||||
| Inhibrx | Formerly VC-backed | La Jolla, CA | ||||
| AC Immune | Formerly VC-backed | Lausanne, Switzerland | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Aileron Therapeutics | Formerly VC-backed | Watertown, MA |
Molecular Partners Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Molecular Partners Patents
Molecular Partners Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240228545-A9 | Charge modified designed repeat domains and their use | Pending | 01-Aug-2022 | ||
| US-20240132546-A1 | Charge modified designed repeat domains and their use | Pending | 31-Jul-2022 | ||
| CA-3239407-A1 | Designed repeat domains with dual binding specificity and their use | Pending | 14-Dec-2021 | ||
| AU-2022413461-A1 | Designed repeat domains with dual binding specificity and their use | Pending | 14-Dec-2021 | ||
| AU-2022252985-A1 | Novel darpin based cd70 engagers | Pending | 09-Apr-2021 | C07K16/2875 |
Molecular Partners Executive Team (14)
| Name | Title | Board Seat |
|---|---|---|
| Patrick Amstutz Ph.D | Chief Executive Officer & Founder | |
| Alexander Zuercher | Chief Operating Officer & Member of the Management Board | |
| Michael Stumpp Ph.D | Founder | |
| Renate Gloggner | Executive Vice President | |
| Kaspar Binz Ph.D | Co-Founder |
Molecular Partners Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Agnete Fredriksen Ph.D | Self | Board Member | |
| Alexander Zuercher | Molecular Partners | Chief Operating Officer & Member of the Management Board | |
| Leo Yip | Self | Board Member | |
| Michael Vasconcelles MD | Self | Board Member | |
| Sandip Kapadia | Self | Board Member |
Molecular Partners Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Molecular Partners Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Molecular Partners ESG
Risk Overview
Risk Rating
Updated May, 19, 2022
24.84 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,480
Rank
Percentile
Pharmaceuticals
Industry
of 905
Rank
Percentile
Biotechnology
Subindustry
of 404
Rank
Percentile
Molecular Partners FAQs
-
When was Molecular Partners founded?
Molecular Partners was founded in 2004.
-
Who is the founder of Molecular Partners?
Patrick Amstutz Ph.D, Michael Stumpp Ph.D, Kaspar Binz Ph.D, Patrik Forrer Ph.D, and Andreas Plückthun Ph.D are the founders of Molecular Partners.
-
Who is the CEO of Molecular Partners?
Patrick Amstutz Ph.D is the CEO of Molecular Partners.
-
Where is Molecular Partners headquartered?
Molecular Partners is headquartered in Zurich, Switzerland.
-
What is the size of Molecular Partners?
Molecular Partners has 167 total employees.
-
What industry is Molecular Partners in?
Molecular Partners’s primary industry is Drug Discovery.
-
Is Molecular Partners a private or public company?
Molecular Partners is a Public company.
-
What is Molecular Partners’s stock symbol?
The ticker symbol for Molecular Partners is MOLN.
-
What is the current stock price of Molecular Partners?
As of 02-Oct-2024 the stock price of Molecular Partners is $4.81.
-
What is the current market cap of Molecular Partners?
The current market capitalization of Molecular Partners is $157M.
-
What is Molecular Partners’s current revenue?
The trailing twelve month revenue for Molecular Partners is $8.86M.
-
Who are Molecular Partners’s competitors?
Bluebird Bio, Inhibrx, AC Immune, CytomX Therapeutics, and Aileron Therapeutics are some of the 56 competitors of Molecular Partners.
-
What is Molecular Partners’s annual earnings per share (EPS)?
Molecular Partners’s EPS for 12 months was -$1.97.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
